Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Shire Reports Strong Phase 3 Data for HAE Drug

By Ryan Bushey | May 19, 2017

Shire is getting closer to regulatory approval for its potential blockbuster drug to treat Hereditary Angioedema (HAE).

The Dublin, Ireland-based drug maker on Thursday reported results from a global, multi-center, randomized, double-blind placebo study evaluating the efficacy and safety of investigational treatment lanadelumab in preventing angioedema attacks in patients 12 years of age or older.

Over a 26-week period, investigators gave 125 patients 150 or 300 mg subcutaneously administered dosages every four weeks or 300 mg every two weeks.

While the data showed all three treatment regimens produced a significantly higher proportion of patients who were attack free throughout the entire study period versus placebo, the 300 mg dose every two weeks elicited the most effective results with a reduced monthly HAE attack frequency of 87 percent compared to placebo. The results were consistent regardless of baseline attack rate.

“In the U.S., available treatment options include either injections for acute attacks or short-acting intravenous infusions administered twice a week,” said Dr. Aleena Banerji, M.D., Massachusetts General Hospital, Boston, MA and clinical trial investigator, in a statement. “If approved, lanadelumab may offer patients a long-acting treatment option that significantly reduces HAE attacks when administered subcutaneously as infrequently as every four weeks.”

About one in 50,000 people are diagnosed with HAE. Patients with this condition deal with recurrent episodes of severe swelling in extremities, upper airways, and the gastrointestinal tract, according to Reuters.

Analysts predict this drug could have blockbuster potential by generating more $2 billion in peak sales, which will help Shire protect and grow its HAE franchise.

The company’s next step is to submit a U.S. marketing application to the U.S. Food and Drug Administration later this year or early 2018 followed by an EU application in the first half of 2018 as well.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE